News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
US Regulators Need More Info on Actelion Ltd. Drug
March 2, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, March 2 (Reuters) - Actelion Ltd needs to do further risk analysis on key drug Tracleer before U.S. regulators decide whether its use can be extended to patients with a less severe form of a rare heart and lung disease.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
Legal
Supreme Court Suspends Injunction Preventing RFK Jr.'s HHS Cuts
July 9, 2025
·
2 min read
·
Tristan Manalac
Tariffs
Trump Threatens 200% Pharma Tariffs—But Gives At Least 1-Year Grace Period
July 9, 2025
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Lilly Gets FDA Label Update for Alzheimer’s Drug To Mitigate Safety Concerns
July 9, 2025
·
2 min read
·
Annalee Armstrong
Podcast
Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More
July 9, 2025
·
1 min read
·
Heather McKenzie